A euploid embryo is one with exactly 46 chromosomes — 23 pairs, no more and no fewer — and it is the strongest single predictor of a successful transfer that IVF can currently offer. In a 2026 New York University Langone cohort, the first single euploid embryo transfer produced a 63.1% live birth rate, and three sequential transfers lifted the cumulative rate to 92.0% — Durbin et al., Fertility and Sterility, 2026.
The limits matter just as much: euploidy predicts implantation with a positive predictive value of only 50-60%, because the endometrium and other “implantation black box” factors still decide individual outcomes — Cimadomo et al., Human Reproduction Update, 2023. Every figure here comes from PubMed-indexed peer-reviewed studies — Durbin 2026, Cimadomo 2023, Victor 2019, Simopoulou 2021, and a 2026 mosaic meta-analysis — compiled by the ProIVF Medical Editing Team and reviewed by the ProIVF Medical Advisory Board.
“A euploid call is the best green light we can measure before transfer — but it signals a 54-63% chance per embryo, not a guarantee. Plan the whole sequence of transfers, not just the first one.” — ProIVF Medical Advisory Board, 2026
Euploid Embryos in One Sentence
Euploid means the embryo carries the normal 46 chromosomes (23 pairs); aneuploid embryos carry one extra or one missing chromosome, and they are the most common cause of implantation failure and early miscarriage. Think of it as checking whether a book has missing or duplicated pages: embryo grade (4AA, 3BB) judges how the cover looks, PGT-M proofreads individual sentences for single-gene disease, and the three systems are independent — none can replace another.
Even morphologically top-grade embryos turn out euploid only about 60-64% of the time, which is why a “perfect-looking” embryo can fail without explanation.
How Is Euploid Status Tested? The 5-Step PGT-A Workflow
The standard way to determine euploidy is PGT-A (preimplantation genetic testing for aneuploidy), and the workflow is fixed in five steps:
- Grow to the blastocyst stage, 5 to 6 days after fertilization — by then the embryo has over one hundred cells, so a sample is representative.
- Trophectoderm biopsy — 5 to 10 cells are taken from the outer ring that will become the placenta, leaving the inner cell mass (the future fetus) untouched.
- Vitrify the embryo while results are pending — freezing first does not reduce developmental potential.
- NGS analysis — the laboratory screens all 24 chromosome types for copy-number abnormalities by next-generation sequencing.
- Report and sequencing — results typically arrive 7 to 14 days after biopsy, and your doctor orders the frozen transfers accordingly.
On biopsy safety: trophectoderm and inner cell mass have already diverged by the blastocyst stage, and decades of data covering millions of cycles have never shown harm to fetal development from sampling the outer ring. The full testing workflow and cost breakdown are in our PGT-A genetic screening guide.
What Are the Three Possible PGT-A Results?
| Result | Meaning | Typical transfer advice |
|---|---|---|
| Euploid (Normal) | All 46 chromosomes present in normal number | Transfer first |
| Aneuploid (Abnormal) | One whole chromosome extra or missing | Generally not transferred; many clinics do not even freeze them |
| Mosaic | Normal and abnormal cell lines mixed within the same embryo | Transferable, prioritized by type and share — see below |
Before acting on the report, confirm the laboratory’s testing platform and its mosaic thresholds, because the cut-offs between low-level and high-level mosaicism differ between labs. Ask your doctor to explain each embryo’s specific chromosome status rather than accepting a one-line count of “how many are normal”.
Does Age Decide the Euploid Rate?
Rising oocyte aneuploidy with age is one of the most established laws in reproductive biology: delaying childbearing lowers mitochondrial function and raises oxidative stress in eggs, which increases division errors and aneuploid embryos — Vergara & García-Velasco, Reproductive BioMedicine Online, 2026. Combined with the age-stratified data verified elsewhere on this site, the overall picture looks like this:
| Egg-retrieval age | Approximate blastocyst euploid rate | Evidence |
|---|---|---|
| Under 35 | about 60-70% | 62.9% euploid among good-quality blastocysts — Li et al., 2022 |
| 33-39 | about 48-64% | 64% for good-quality vs 48% for lower-quality — McDaniel et al., 2021 |
| Over 40 | about 10-30% | oocyte aneuploidy already runs 60-80% at these ages — IVF success-rate data |
Two practical corollaries follow. AMH reflects egg quantity, not quality — a 40-year-old with normal AMH still faces age-driven aneuploidy rates.
Age also matters far more for obtaining a euploid embryo than for transferring one: once a euploid embryo is in hand, transfer live birth rates at 42 approach those at 30. That is why “retrieve more, bank euploid embryos, transfer one at a time” has become the default strategy for later reproduction; see our IVF success rates by age guide.
What Are the Real Success Rates of Euploid Transfers?
NYU Langone reviewed 5,811 patients and 7,763 single euploid embryo transfers performed between 2014 and 2024 — Durbin et al., 2026 — and the numbers are clearest when per-transfer and cumulative views are kept apart:
| Transfer number | Live birth rate for that transfer | Cumulative live birth rate |
|---|---|---|
| 1st | 63.1% | 63.1% |
| 2nd | 54.0% | about 80% (modeled) |
| 3rd | steady near 54% | 92.0% |
| 5th | steady near 54% | 98.3% |
| 6th | steady near 54% | 98.8% |
Three takeaways for planning:
- Each euploid transfer is an independent event — a first failure does not chain-fail the rest, because per-transfer rates settle onto a plateau of roughly 54% from the second transfer onward and stop declining.
- Fewer than 5% of patients with banked euploid embryos still meet the definition of recurrent implantation failure after three transfers, and fewer than 2% are without a live birth after five, so “keep transferring” is itself the evidence-based first-line strategy — Durbin 2026.
- These figures match our site-wide data: screened transfers at 38 and over run about 50-60% live birth per transfer, versus 8-25% without screening — IVF success-rate data.
Why Do Euploid Embryos Still Fail? The Implantation Black Box
The ceiling is well documented: a systematic review and meta-analysis of 41 studies puts the positive predictive value of PGT-A euploidy for implantation at no more than 50-60% — Cimadomo et al., 2023.
The remaining 30-40% of failures sit outside the embryo: endometrial receptivity and chronic endometritis, fluid-filled fallopian tubes, adenomyosis and endometriosis, the transfer procedure itself, and embryo regulatory defects no current test can see. The same group’s follow-up cohort also suggests that repeated freeze-thaw-transfer rounds slightly lower a euploid embryo’s implantation potential — Reproductive Biology and Endocrinology, 2024, which favors preparing the uterus thoroughly before each transfer instead of rapid-fire sequencing. For the full post-failure workup — and which tests are actually worth doing — see Why good embryos fail to implant.
What Should You Do About Mosaic Embryos?
Mosaic results are the hardest call, and they come up when no euploid embryo is left to transfer. A 2026 meta-analysis pooling 8 studies — 1,904 mosaic transfers versus 9,332 euploid transfers — gives the most complete stratified answer to date — Reproductive BioMedicine Online, 2026:
- Pooled across studies, mosaic transfers show lower live birth / ongoing pregnancy than euploid transfers (RR 0.74) and slightly higher miscarriage (RR 1.57).
- Much of that gap looks like selection bias: in the only double-blind study, where neither doctors nor patients knew the embryo classification, mosaic outcomes at all levels matched euploid results (RR 0.98) — mosaic embryos tend to be assigned to patients with fewer alternatives, which drags their numbers down.
- Type matters more than the label: segmental mosaicism behaves close to euploid (RR 0.90), while whole-chromosome mosaicism performs clearly worse (RR 0.60).
- Complexity works like a dose curve: live birth / ongoing pregnancy ran 52.3% in the euploid group, 43.1% for segmental mosaic, 32.5% for one whole chromosome, 27.2% for two, and just 20.8% for three or more complex mosaic types.
In practice this becomes a transfer priority ranking: euploid first, then low-level segmental mosaics, then single whole-chromosome mosaics (trisomies preferred over monosomies), complex mosaics last — carried out only in experienced centers, with amniocentesis to confirm during pregnancy. One caveat on biopsy limits: a concordance study of 100 donated blastocysts found trophectoderm sampling reads whole-chromosome abnormalities well but segmental ones less reliably — Victor et al., Human Reproduction, 2019. Embryos called mosaic — or even aneuploid — are therefore not always mislabeled embryos, which is one reason cautious mosaic transfer is accepted internationally.
Euploid Status or Embryo Grade — Which Should You Trust?
Morphology grades what an embryo looks like; PGT-A answers whether its chromosomes are right. In an NGS-based PGT-A cohort of advanced-maternal-age patients, euploid embryos implanted at essentially the same rate whether their morphology was AA or BC — Journal of Assisted Reproduction and Genetics, 2019.
Once you hold a euploid report, prettier letters should no longer be the main reason to order one transfer before another. Morphology still earns its place upstream — it guides which embryos to culture and biopsy in the first place. For how the two systems fit together and how to read each report, see our embryo grading guide.
Should Everyone Have PGT-A? Where the Evidence Stops
To be candid: PGT-A has not been shown to raise live birth rates in every group. A network meta-analysis of 11 randomized controlled trials found no significant gain in per-patient live birth across the general infertility population (RR 1.11), but a clearly lower miscarriage rate (RR 0.45) and a higher cumulative live birth rate (RR 1.36) — Simopoulou et al., J Assist Reprod Genet, 2021.
The subgroup detail matters. Strata by age show clear benefit from 35 upward (RR 1.29) and none below 35 (RR 0.92), and biopsy timing favors day-5 blastocysts over day-3 cleavage-stage biopsy.
Translated into plain terms: PGT-A’s real value is fewer miscarriages and fewer wasted transfers — the test spends your transfer windows well rather than turning every embryo into a baby. Younger patients with ample embryo reserves and a short failed-transfer history should weigh the time and cost with their doctor before adding it. Costs and country-by-country price gaps are broken down in our PGT-A guide.
FAQ
Q: Can a euploid embryo transfer still end in miscarriage?
Yes — but far less often than with unscreened embryos: clinical miscarriage after euploid transfer tracks the population baseline of roughly 10-15% (slightly higher at advanced maternal age).
In the 2026 NYU cohort, miscarriage and biochemical pregnancy rates stayed stable across successive single euploid transfers — Durbin 2026 — and pooled randomized-trial evidence puts PGT-A’s miscarriage-rate reduction at about half (RR 0.45, Simopoulou 2021). If losses continue despite euploid transfers, the workup should target endometrial and maternal factors, not chromosome number.
Q: My report says mosaic — is that embryo useless?
No, real-world mosaic outcomes are much better than most patients assume: segmental mosaics reach live birth rates close to euploid (RR 0.90), and in the double-blind study mosaic embryos at every grade matched euploid results.
When no euploid embryo remains, ranking mosaic embryos with your doctor by type, share, and complexity is an internationally accepted option, with amniocentesis confirming the result during pregnancy.
Q: Why is the second euploid transfer less successful than the first?
The likelier explanation is sequencing: clinics transfer the best-graded, best freezing-surviving embryo first, so the 63.1% figure for transfer one includes a ranking bonus. From transfer two onward, results settle onto a durable plateau of about 54% per transfer — the data basis for keeping transfers going while euploid embryos remain in storage — Durbin 2026.
Q: Can male factors affect embryo euploidy?
Maternal age and egg quality drive most aneuploidy; a 2026 cohort of advanced-maternal-age women found that the sperm DNA fragmentation index (SCSA DFI) did not change the euploid rate among blastocysts usable for testing — Andrology, 2026 — but high fragmentation still correlates with fertilization, embryo development, and miscarriage risk, so the male workup should not be skipped.
Q: Where should I have PGT-A done?
PGT-A interpretation depends heavily on the sequencing platform and the embryology team’s experience: shortlist clinics by their blastocyst culture rates, whether they run their own genetics laboratory, and their published mosaic-management and follow-up protocols — a benchmark for screened programs is live birth around 54-63% per transfer.
You can filter clinics offering PGT-A by country in the ProIVF hospital directory and compare each center’s euploid yield and transfer data.
What Should You Do After Getting Your PGT-A Report? A 5-Step Checklist
Five moves turn the report into a plan:
- Request the full per-embryo report. Confirm each embryo’s chromosome call and mosaic percentage instead of accepting a verbal “X embryos are normal”.
- Ask how transfer order is set. Euploid first is the rule; ask what breaks ties within the same tier.
- Complete the uterine assessment before any transfer — endometrial thickness and pattern, chronic endometritis screening, hydrosalpinx evaluation — rather than placing a euploid embryo into an unprepared environment.
- Do the inventory math. Euploid embryo count × the 54-63% live birth rate per transfer, weighed against storage fees and future transfer cycles, decides whether to bank more eggs or change plans.
- Line up the mosaic confirmation path. Agree the prenatal diagnostic plan (amniocentesis) with your doctor before transfer, then keep the follow-up schedule.
When choosing where to have PGT-A done, laboratory configuration and data transparency are the core diligence items — our how-to-choose-an-IVF-clinic guide carries the full question checklist. For a second opinion on your own report or destination options, reach out through our contact page.
Medical disclaimer: This article is health education information and does not constitute medical diagnosis, treatment, or medication advice. Whether PGT-A applies to you, whether to transfer mosaic embryos, and how to sequence transfers are individualized decisions your reproductive specialist should make with your full medical history. Any medication adjustment must be made under professional supervision.
References
- Durbin C, et al. Cumulative probability of a live birth after up to six sequential single euploid embryo transfers. Fertility and Sterility 2026. PMID: 42508682
- Cimadomo D, et al. Opening the black box: why do euploid blastocysts fail to implant? A systematic review and meta-analysis. Human Reproduction Update 2023. PMID: 37192834
- Cristóbal Quevedo I, Cristóbal Garcia I. Mosaic embryo transfer versus euploid embryo transfer after PGT-A: a systematic review and meta-analysis. Reproductive BioMedicine Online 2026. PMID: 42600547
- Simopoulou M, et al. PGT-A: who and when? A systematic review and network meta-analysis of RCTs. J Assist Reprod Genet 2021. PMID: 34036455
- Victor AR, et al. Assessment of aneuploidy concordance between clinical trophectoderm biopsy and blastocyst. Human Reproduction 2019. PMID: 30418565
- Vergara V, García-Velasco JA. Delayed childbearing and its impact. Reproductive BioMedicine Online 2026. PMID: 42288049
This article was written by the ProIVF Medical Editing Team and reviewed by the ProIVF Medical Advisory Board.
It is based on peer-reviewed, PubMed-indexed literature — including the Durbin 2026 euploid transfer cohort, the Cimadomo 2023 implantation-failure systematic review, and the 2026 mosaic transfer meta-analysis — together with CDC and SART official registry data, with every statistic linked to its original source. Last updated: September 21, 2026.
